Bioverativ Stock Price, News & Analysis (NASDAQ:BIVV)

$62.32 -1.55 (-2.43 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$62.32
Today's Range$62.27 - $64.90
52-Week Range$40.99 - $65.09
Volume926,106 shs
Average Volume1.12 million shs
Market Capitalization$6.74 billion
P/E Ratio15.24
Dividend YieldN/A
BetaN/A

About Bioverativ (NASDAQ:BIVV)

Bioverativ logoBioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.01%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E Ratio15.2371638141809
Forward P/E Ratio24.44
P/E Growth1.4

Sales & Book Value

Annual Sales$887.40 million
Price / Sales7.60
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$4.09
Net Income$439.60 million
Net Margins40.44%
Return on Equity69.03%
Return on Assets40.94%

Miscellaneous

Employees350
Outstanding Shares108,200,000

Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) posted its quarterly earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.25. The biotechnology company earned $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. Bioverativ's revenue was up 27.2% on a year-over-year basis. View Bioverativ's Earnings History.

When will Bioverativ make its next earnings announcement?

Bioverativ is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Bioverativ.

Where is Bioverativ's stock going? Where will Bioverativ's stock price be in 2018?

16 brokerages have issued 12-month price objectives for Bioverativ's stock. Their forecasts range from $47.00 to $80.00. On average, they anticipate Bioverativ's share price to reach $60.36 in the next year. View Analyst Ratings for Bioverativ.

What are Wall Street analysts saying about Bioverativ stock?

Here are some recent quotes from research analysts about Bioverativ stock:

  • 1. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
  • 2. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)

Who are some of Bioverativ's key competitors?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:

  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

Who owns Bioverativ stock?

Bioverativ's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.32%), DnB Asset Management AS (0.16%), Bank of Montreal Can (0.14%), Gateway Investment Advisers LLC (0.12%), Nisa Investment Advisors LLC (0.05%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.

Who sold Bioverativ stock? Who is selling Bioverativ stock?

Bioverativ's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Nisa Investment Advisors LLC, Convergence Investment Partners LLC, AMI Asset Management Corp and Louisiana State Employees Retirement System. View Insider Buying and Selling for Bioverativ.

Who bought Bioverativ stock? Who is buying Bioverativ stock?

Bioverativ's stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Gateway Investment Advisers LLC, Schwab Charles Investment Management Inc. and Aurora Investment Counsel. Company insiders that have bought Bioverativ stock in the last two years include Alexander J Denner, Brian S Posner and Louis J Paglia. View Insider Buying and Selling for Bioverativ.

How do I buy Bioverativ stock?

Shares of Bioverativ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioverativ's stock price today?

One share of Bioverativ stock can currently be purchased for approximately $62.32.

How big of a company is Bioverativ?

Bioverativ has a market capitalization of $6.74 billion and generates $887.40 million in revenue each year. The biotechnology company earns $439.60 million in net income (profit) each year or $4.09 on an earnings per share basis. Bioverativ employs 350 workers across the globe.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]


MarketBeat Community Rating for Bioverativ (BIVV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioverativ (NASDAQ:BIVV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.442.442.442.43
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $60.36$60.36$60.79$55.42
Price Target Upside: 18.91% upside18.91% upside5.90% upside8.11% downside

Bioverativ (NASDAQ:BIVV) Consensus Price Target History

Price Target History for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ:BIVV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017Deutsche BankSet Price TargetHold$53.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$71.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingUnderweight$45.00 -> $47.00N/AView Rating Details
9/20/2017ArgusUpgradeHold -> Buy$64.00MediumView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform -> Sector Perform$59.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$58.00HighView Rating Details
8/9/2017Jefferies GroupReiterated RatingBuy$67.00 -> $70.00LowView Rating Details
8/4/2017CowenReiterated RatingBuy$80.00HighView Rating Details
6/28/2017William BlairInitiated CoverageMkt Perform -> Market PerformLowView Rating Details
6/28/2017WedbushReiterated RatingMarket PerformLowView Rating Details
5/24/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$47.00 -> $52.00HighView Rating Details
4/24/2017GabelliDowngradeBuy -> HoldLowView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$62.00LowView Rating Details
3/27/2017Stifel NicolausBoost Price TargetBuy -> Buy$54.00 -> $57.00LowView Rating Details
3/13/2017Goldman Sachs GroupDowngradeBuy -> Neutral$55.00MediumView Rating Details
2/7/2017Raymond James FinancialInitiated CoverageStrong-Buy$59.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Bioverativ (NASDAQ:BIVV) Earnings History and Estimates Chart

Earnings by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.57N/AView Earnings Details
10/26/2017Q3 2017$0.55$0.80$285.45 million$291.60 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.71$0.88$269.00 million$289.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.62$0.65ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bioverativ (NASDAQ:BIVV) Earnings Estimates

Current Year EPS Consensus Estimate: $2.55 EPS
Next Year EPS Consensus Estimate: $3.26 EPS

Dividends

Dividend History for Bioverativ (NASDAQ:BIVV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 96.03%
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2017Brian S PosnerDirectorBuy1,000$59.19$59,190.006,693View SEC Filing  
8/7/2017Louis J PagliaDirectorBuy2,000$59.70$119,400.005,056View SEC Filing  
6/28/2017Diantha DuvallInsiderSell818$60.47$49,464.462,128View SEC Filing  
5/30/2017Alexander J DennerDirectorBuy90,000$55.93$5,033,700.005,001View SEC Filing  
5/26/2017Louis J PagliaDirectorBuy2,000$57.76$115,520.003,056View SEC Filing  
5/24/2017Brian S PosnerDirectorBuy2,000$53.86$107,720.004,993View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bioverativ (NASDAQ BIVV) News Headlines

Source:
DateHeadline
Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018
finance.yahoo.com - January 16 at 4:58 PM
Bioverativ Inc (BIVV) Receives Average Rating of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 8:00 AM
 Analysts Anticipate Bioverativ Inc (BIVV) Will Announce Quarterly Sales of $308.45 Million Analysts Anticipate Bioverativ Inc (BIVV) Will Announce Quarterly Sales of $308.45 Million
www.americanbankingnews.com - January 15 at 10:04 PM
William Blair Weighs in on Bioverativ Incs FY2017 Earnings (BIVV)William Blair Weighs in on Bioverativ Inc's FY2017 Earnings (BIVV)
www.americanbankingnews.com - January 12 at 7:32 AM
Bioverativ Inc (BIVV) PT Raised to $100 at Cowen - StreetInsider.com - StreetInsider.comBioverativ Inc (BIVV) PT Raised to $100 at Cowen - StreetInsider.com - StreetInsider.com
www.streetinsider.com - January 10 at 9:58 AM
Pre-Open Movers 01/09: (ATUS) (PSTI) (GBT) Higher; (AXSM) (BGFV) (D) Lower (more...)Pre-Open Movers 01/09: (ATUS) (PSTI) (GBT) Higher; (AXSM) (BGFV) (D) Lower (more...)
www.streetinsider.com - January 9 at 5:03 PM
Bioverativ (BIVV) Upgraded by Zacks Investment Research to BuyBioverativ (BIVV) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 8 at 7:52 PM
Bioverativ (BIVV) Cut to "Hold" at Zacks Investment ResearchBioverativ (BIVV) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 3 at 5:40 PM
Bioverativ to Present at the 2018 J.P. Morgan Healthcare ConferenceBioverativ to Present at the 2018 J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:03 PM
Bioverativ (BIVV) Rating Increased to Buy at Zacks Investment ResearchBioverativ (BIVV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 1 at 5:20 PM
ETFs with exposure to Bioverativ, Inc. : December 27, 2017ETFs with exposure to Bioverativ, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 5:58 PM
Financial Survey: Bioverativ (BIVV) and Cytokinetics (CYTK)Financial Survey: Bioverativ (BIVV) and Cytokinetics (CYTK)
www.americanbankingnews.com - December 27 at 5:34 AM
Bioverativ Sees Unusually High Options Volume (BIVV)Bioverativ Sees Unusually High Options Volume (BIVV)
www.americanbankingnews.com - December 23 at 2:10 AM
Bioverativ Announces 2018 Annual Meeting of StockholdersBioverativ Announces 2018 Annual Meeting of Stockholders
finance.yahoo.com - December 22 at 8:07 PM
Bioverativ Inc (BIVV) Given Consensus Rating of "Hold" by AnalystsBioverativ Inc (BIVV) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 8:50 AM
ETFs with exposure to Bioverativ, Inc. : December 14, 2017ETFs with exposure to Bioverativ, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:32 PM
Bioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in CAgD PatientsBioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in CAgD Patients
www.streetinsider.com - December 12 at 5:24 PM
Bioverativ Inc. (BIVV) Reports New Data Showing Extended Prophylactic Dosing with ALPROLIX Provides Safe and ... - StreetInsider.comBioverativ Inc. (BIVV) Reports New Data Showing Extended Prophylactic Dosing with ALPROLIX Provides Safe and ... - StreetInsider.com
www.streetinsider.com - December 12 at 10:18 AM
Bioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b ... - StreetInsider.comBioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b ... - StreetInsider.com
www.streetinsider.com - December 12 at 10:18 AM
BRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patientsBRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients
www.reuters.com - December 11 at 5:11 PM
Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) PatientsBioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
finance.yahoo.com - December 11 at 5:11 PM
New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia BNew Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
finance.yahoo.com - December 11 at 10:36 AM
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint ... - Business Wire (press release)Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint ... - Business Wire (press release)
www.businesswire.com - December 10 at 5:12 PM
Study Shows Weekly Prophylactic Treatment with ELOCTATE ... - Business Wire (press release)Study Shows Weekly Prophylactic Treatment with ELOCTATE ... - Business Wire (press release)
www.businesswire.com - December 10 at 5:12 PM
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia AStudy Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
finance.yahoo.com - December 10 at 9:48 AM
ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging StudyALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
finance.yahoo.com - December 9 at 9:53 AM
ETFs with exposure to Bioverativ, Inc. : December 4, 2017ETFs with exposure to Bioverativ, Inc. : December 4, 2017
finance.yahoo.com - December 4 at 4:59 PM
Comparing Bioverativ (BIVV) and Its RivalsComparing Bioverativ (BIVV) and Its Rivals
www.americanbankingnews.com - November 29 at 7:28 PM
BRIEF-Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For AlprolixBRIEF-Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For Alprolix
www.reuters.com - November 28 at 4:56 PM
Bioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIXBioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX
www.streetinsider.com - November 28 at 4:56 PM
Bioverativ is Now Oversold (BIVV) - NasdaqBioverativ is Now Oversold (BIVV) - Nasdaq
www.nasdaq.com - November 27 at 6:32 PM
Bioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX - StreetInsider.comBioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX - StreetInsider.com
www.streetinsider.com - November 27 at 6:32 PM
U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia BU.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B
finance.yahoo.com - November 27 at 6:32 PM
Bioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 7:46 AM
Bioverativ: A Rare Pearl In Biotech - Seeking AlphaBioverativ: A Rare Pearl In Biotech - Seeking Alpha
seekingalpha.com - November 25 at 3:39 PM
ETFs with exposure to Bioverativ, Inc. : November 24, 2017ETFs with exposure to Bioverativ, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 11:29 AM
Investors Buy Large Volume of Bioverativ Put Options (BIVV)Investors Buy Large Volume of Bioverativ Put Options (BIVV)
www.americanbankingnews.com - November 24 at 1:58 AM
Bioverativ IncBioverativ Inc
www.bloomberg.com - November 22 at 4:13 AM
Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceBioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 21 at 11:12 PM
Bioverativ Inc (BIVV) Given a $53.00 Price Target at Deutsche Bank AGBioverativ Inc (BIVV) Given a $53.00 Price Target at Deutsche Bank AG
www.americanbankingnews.com - November 21 at 8:15 PM
ETFs with exposure to Bioverativ, Inc. : November 13, 2017ETFs with exposure to Bioverativ, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 1:05 AM
Relative Strength Alert For BioverativRelative Strength Alert For Bioverativ
www.nasdaq.com - November 2 at 5:12 PM
ETFs with exposure to Bioverativ, Inc. : November 2, 2017ETFs with exposure to Bioverativ, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:12 PM
Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)
www.americanbankingnews.com - November 2 at 9:28 AM
Bioverativ Inc (BIVV) Receives Average Recommendation of "Hold" from BrokeragesBioverativ Inc (BIVV) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 8:43 AM
Bioverativ Inc (BIVV) Cut to Hold at Zacks Investment ResearchBioverativ Inc (BIVV) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 6:28 PM
Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 5:10 PM
Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual MeetingBioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting
finance.yahoo.com - November 1 at 5:10 PM
Bioverativ to Present at the Credit Suisse 2017 Healthcare ConferenceBioverativ to Present at the Credit Suisse 2017 Healthcare Conference
finance.yahoo.com - November 1 at 5:10 PM
Http://www.sobi.comHttp://www.sobi.com
www.thestreet.com - October 31 at 10:41 PM

SEC Filings

Bioverativ (NASDAQ:BIVV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioverativ (NASDAQ BIVV) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.